Medtronic Delivers on FY25 Sustainability Targets and Charts Path to 2030

A landmark year for the company's impact journey, Medtronic not only achieved but also exceeded its Scope 1 and 2 emissions intensity target in FY25

NORTHAMPTON, MA / ACCESS Newswire / October 8, 2025 / Medtronic plc, a global healthcare technology leader, has released its fiscal year 2025 (FY25) Impact Report, "Unlocking the future of health," detailing progress toward its impact goals. A landmark year for the company's impact journey, Medtronic not only achieved but also exceeded its Scope 1 and 2 emissions intensity target in FY25, reducing emissions by 60% versus a 50% target. This was made possible, in part, through sourcing 50% of energy from renewable and alternative sources.

"For over 75 years, we have been driven by a pioneering spirit; that same spirit continues to shape our future," said Geoff Martha, Medtronic chairman and CEO. "It's what pushes us to improve people's health through cutting-edge innovations. It's also what motivates us to minimize our environmental footprint and support the employees and partners that make our business possible."

The Medtronic FY25 Impact Report details the following notable achievements:

Patients: Driving innovation to improve health outcomes and expand access

Reinforcing its commitment to put patients first and elevate standards of care, Medtronic seeks to transform patient experiences by making them more personalized, connected, and accessible. In FY25, the company:

• Expanded access and affordability by serving more than 79 million patients, raising the goal to serve 82 million patients in FY26.

• Exceeded product quality goal by implementing key design changes in selected products and maintaining a focus on product safety, which resulted in a 34% reduction in aggregate product complaints in FY25, surpassing our goal of 10%.

• Advanced product innovation, surpassing its commitment to flow 20% of revenue from new products and therapies¹ to R&D innovation.

• Alleviated the healthcare practitioner shortfall, training over 1.15 million healthcare professionals over the past three years to support better patient outcomes, toward a goal of 1.2 million by FY26.

• Improved outcomes through more inclusive solutions. To address disparities in pulse oximetry readings, which can overestimate oxygen levels in patients with darker skin, Medtronic opened a clinical physiology lab in Denver, completed four premarket trials, and educated 17,000 clinicians on how skin pigmentation affects readings.

So handeln Sie das Kursziel

Der Analyst erwartet ein Kursziel von 83,73$, was einem Rückgang von -9,19% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.

 

Morgan Stanley

 

Alle Partner

Übernehmen

Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
Bitte verändern Sie Kursziel, Zeitraum oder Emittent.Alternativ können Sie auch unsere Derivate-Suchen verwenden
Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche

Werbung Disclaimer